- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04804891
Using T-Cell Alloreactivity and Chimerism to Guide Immunosuppression Minimization in Intestinal Transplantation
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Abdominal trauma, congenital abnormalities and ischemic injury cause intestinal damage that prevents the digestion and absorption of fluids and nutrients essential for life. Intestinal transplantation is life-saving for patients with complications related to the administration of intravenous nutrients. Approximately 100-160 intestinal transplants (ITx) are performed in the US annually. However, patient survival rates are far from optimal, due to high rejection rates resulting from an immune attack of the recipient against the donor, termed host-vs-graft (HVG) reactivity The high levels of global immunosuppression used to prevent rejection come with a high risk of infections and malignant disease (i.e. lymphoma). Thus, there is an urgent need for a well-tolerated treatment strategy that controls rejection while reducing these risks. Immune tolerance, in which the immune system regards the donor as "self" so that long-term graft acceptance is achieved without life-long immunosuppression, would accomplish this goal . Infusion of bone marrow cells from the same donor of the solid organs could promote a state called "mixed chimerism" in which both donor cells and recipient cells coexist in the body. Mixed chimerism has been shown to induce tolerance to the transplanted organ in animal models and in patients receiving kidney transplants.
The investigators propose studies to promote tolerance induction in intestinal transplant recipients by administering donor bone marrow stem cells to promote lasting mixed chimerism. The investigators' proposal builds on their demonstration that mixed chimerism commonly occurs in intestinal transplant (ITx) recipients without bone marrow transplant, and that its presence correlates with reduced rejection rates. However, this mixed chimerism is not permanent. The investigators have discovered that there are bone marrow stem cells in the donor intestinal grafts and that some of these survive and enter the bone marrow of the recipient. This process is facilitated by a phenomenon called a "lymphohematopoietic graft-vs-host responses (LGVHR)", in which T lymphocytes from the ITx donor attack recipient blood-forming cells to make "space" for their own establishment in the bone marrow, but do not induce GVHD. The investigators have also obtained evidence that this immune response suppresses rejection of the graft.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Clinical Research Core
- Phone Number: 212-305-3839
- Email: tk2388@cumc.columbia.edu
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- Recruiting
- Columbia University Irving Medical Center/NYP
-
Contact:
- Clinical Research Core
- Phone Number: 212-305-3839
- Email: tk2388@cumc.columbia.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
All patients actively listed as candidates for intestinal or multi-visceral transplant at the study site; while all patients who are actively listed in United Network for Organ Sharing (UNOS) for intestinal and/or multi-visceral transplantation, including those who have previously received a multi-visceral transplant and are re-listed, are eligible for participation, the following are examples of listing criteria suitable for enrollment in this clinical trial:
Short Bowel Syndrome (SBS) due to:
- Trauma (multiple resections/explorations and/or vascular abdominal trauma superior mesenteric artery (SMA) / superior mesenteric vein (SMV) injuries)
- Gastroschisis
- Volvulus
- Necrotizing Enterocolitis
- Intestinal Atresia
- Crohn's Disease
- Hirschprung's Disease
- Chronic Intestinal Pseudo-Obstruction
Malabsorption:
- Microvillus Inclusion Disease
- Tufting Enteropathy
- Complete portomesenteric thrombosis with cirrhosis
Slow-growing, low-malignancy potential tumors infiltrating mesenteric root:
- Gardner's Syndrome
- Familial Adenomatous Polyposis
- Desmoid Tumor with Intra-Abdominal Infiltration
- Endocrine Tumors
- Re-transplant candidates who lost the first graft to rejection or patients who have higher risk of toxicity from chronic long term immunosuppression (i.e., patients with chronic kidney disease)
- Patient commits to planned follow up at a study site for the 48-month duration of study procedures
- Age ≥18 years old and ≤65 years old
- Subjects or capable of signing the informed consent document themselves
Exclusion Criteria:
- Active systemic infection with hemodynamic instability and/or sepsis
- Patients with known immunodeficiency syndrome
- Carcinoma with metastasis (except neuro-endocrine tumors, even in the presence of metastasis these patients may undergo multivisceral/cluster transplantation)
- Severe cardiovascular and/or respiratory instability, as defined by requirement of pressors or ventilator
- Severe cerebral edema, with radiologic findings of effaced sulci and/or herniation
- Poorly controlled hypertension (systolic blood pressure > 170 on at least 2 occasions), diabetes mellitus (HbA1c > 8), or uncontrollable seizure disorders
- Age > 65 years
- Documented history of non-compliance with medical therapy and follow-up
- Substance addiction in the last six months
- Psychosocial Instability: absence of a consistent reliable social support system
- Significant or active psychiatric disorder associated with the inability to cooperate or comply with medical therapy
- In the judgement of the clinical team, severely limited functional status with poor rehabilitation potential
- Multi-organ failure and preceding CD34+ infusion
- Pre formed panel reactive antibodies (PRA) mean fluorescein intensity (MFI) > 5000 by Luminex
- Patients who are pregnant or breast-feeding or intend to get pregnant during the study period
- Patients who have developed moderate or severe rejection before post-transplant day 11
- Vulnerable populations, such as incarcerated or institutionalized individuals
- Subjects with clinical features suggestive of GVHD
- Subjects who are hemodynamically unstable (i.e., requiring vasopressor support)
- Female subjects of childbearing age and male patients who are not using and/or unwilling to use an effective method of birth control for the duration of the trial activities
- History of previous hematopoietic progenitor cell (HPC) infusion or transplant of any kind. Note: Human leukocyte antigen (HLA) mismatch will not be one of the exclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cell Therapy
Patients will receive an infusion containing 1x106/kg CD34+ cells.
No more than 104 CD34+ T cells per kg recipient weight will be included in the infusion.
Cadaveric donor CD34 cell infusion will occur at any time between post-operative day 11 to day 13 following transplantation.
|
Infusion of containing 1x106/kg CD34+ cells from donor bone marrow selected using the CliniMACS® CD34 Reagent System.
|
No Intervention: Control
Patients who do not consent to receive donor CD34 cell infusion or whose donor family declines consent for research use of donor bone marrow will receive their usual standard of care.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total number of participants with moderate to severe GVHD
Time Frame: Up to 4 years after transplantation
|
Total number of participants with moderate to severe (at least Grade II) graft-versus-host disease (GVHD) will be monitored.
|
Up to 4 years after transplantation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Graft survival rate
Time Frame: Up to 1 month after transplantation
|
Percentage of individuals with graft survival.
|
Up to 1 month after transplantation
|
Retention rate
Time Frame: Up to 1 month after transplantation
|
Percentage of individuals with retention from any cause.
|
Up to 1 month after transplantation
|
Graft survival rate
Time Frame: Up to 1 year after transplantation
|
Percentage of individuals with graft survival.
|
Up to 1 year after transplantation
|
Retention rate
Time Frame: Up to 1 year after transplantation
|
Percentage of individuals with retention from any cause.
|
Up to 1 year after transplantation
|
Graft survival rate
Time Frame: Up to 3 years after transplantation
|
Percentage of individuals with graft survival.
|
Up to 3 years after transplantation
|
Retention rate
Time Frame: Up to 3 years after transplantation
|
Percentage of individuals with retention from any cause.
|
Up to 3 years after transplantation
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Tomoaki Kato, MD, Columbia University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- AAAS8908
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intestinal Transplantation
-
Shanghai 10th People's HospitalCompletedSmall Intestinal Bacterial Overgrowth | Fecal Microbiota TransplantationChina
-
The Second Hospital of Nanjing Medical UniversityThe First Affiliated Hospital of Guangdong Pharmaceutical University; Wuxi... and other collaboratorsNot yet recruitingBowel Obstruction | Fecal Microbiota TransplantationChina
-
Helsinki University Central HospitalUniversity of HelsinkiActive, not recruitingFecal Microbiota Transplantation | Cesarean Section, Affecting Fetus or Newborn | Intestinal MicrobiomeFinland
-
Shanghai 10th People's HospitalCompletedFecal Microbiota Transplantation | Intestinal Pseudo-ObstructionChina
-
The First Affiliated Hospital of Nanchang UniversityCompletedAcute Pancreatitis | Intestinal Bacteria Flora Disturbance | Fecal Microbiota Transplantation | Intestinal DysfunctionChina
-
First Affiliated Hospital of Chengdu Medical CollegeUnknownAcute Pancreatitis | Intestinal Bacteria Flora Disturbance | Fecal Microbiota Transplantation | Intestinal DysfunctionChina
-
University Hospital, MontpellierUniversité MontpellierCompletedLiver Transplantation | Intestinal Fistula | Digestive System Fistula | Intestinal PerforationFrance
-
Astellas Pharma Europe Ltd.Active, not recruitingLiver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine TransplantationBelgium, Czechia, France, Germany, Italy, Poland, United Kingdom
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedKidney Transplantation | Renal Transplantation | Transplantation, Kidney | Grafting, Kidney | Transplantation, RenalBelgium, Germany, Spain, Sweden, Italy, Switzerland, United Kingdom, Austria, France, Poland, Czech Republic, Netherlands
-
Astellas Pharma Europe Ltd.CompletedLiver Transplantation | Kidney Transplantation | Heart TransplantationCzechia, France, Italy, Poland, United Kingdom
Clinical Trials on Cell Therapy
-
Royan InstituteTehran University of Medical Sciences; Shahid Beheshti University of Medical...UnknownCovid-19Iran, Islamic Republic of
-
Nantes University HospitalUnknown
-
General Hospital of Chinese Armed Police ForcesUnknownHereditary Cerebellar Ataxia.China
-
Anhui Provincial HospitalEnrolling by invitationCirrhosis, LiverChina
-
Lung InstituteCompletedInterstitial Lung Disease | COPDUnited States
-
Ministry of Health, BrazilCompletedCoronary Artery Disease | Angina Pectoris | Chronic Ischemic Heart DiseaseBrazil
-
National Heart, Lung, and Blood Institute (NHLBI)NIH Heart Center at Suburban HospitalTerminatedCoronary Artery Disease | Ischemic Heart Disease | Heart Disease | Coronary Artery Disease (CAD)United States
-
Chinese Academy of SciencesNational Natural Science Foundation of China; The First Affiliated Hospital...Active, not recruitingPrimary Ovarian InsufficiencyChina
-
Medical University of ViennaOdense University Hospital; Karolinska Institutet; The University of Texas Health... and other collaboratorsCompleted
-
Lung InstituteCompletedInterstitial Lung Disease | COPDUnited States